Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival.

Click to increase image sizeClick to decrease image size AcknowledgementsThis registry was granted by Celgene and Novartis. We thank M. Hellmich (Institute of Medical Statistics and Computational Biology, Cologne, Germany) for statistical support and all participating hematologists for the contribution of data.Disclosure statementThe authors report no conflicts of interest.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.